Clinical trial · Observational
Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)
NCT04068168CI-TRIAL-00097315Imfinzi PMScompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objectives of this study are to assess safety and efficacy of Imfinzi (durvalumab) in a real world setting in patients treated with Imfinzi under the approved indication in Korea.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer, Biliary Tract Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.85 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Safety (AE, SAE, ADR, SADR, AESI, DAE, fatal AE)
- timeFrame
- for up to 1 year after the first dose of Imfinzi
- description
- safety outcome
- measure
- Dose interruptions
- timeFrame
- for up to 1 year after the first dose of Imfinzi
- description
- Safety outcome
- measure
- Duration of treatment
- timeFrame
- for up to 1 year after the first dose of Imfinzi
- description
- Safety outcome
Secondary outcomes (3)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Eligible for Imfinzi treatment according to the approved label * Provision of signed and dated written informed consent by the patient or legally acceptable representative Exclusion Criteria: * Current participation in any interventional trial * Other off-label indications according to the approved label
References
Publications (0)
Data not yet available
No reference posted for this study.